Utah Medical Products, Inc. (UTMD) Income Statement Analysis

See more : Integral Ad Science Holding Corp. (IAS) Income Statement Analysis – Financial Results

Complete financial analysis of Utah Medical Products, Inc. (UTMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Utah Medical Products, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.

You may be interested

Utah Medical Products, Inc. (UTMD)

Industry: Medical - Instruments & Supplies

Sector: Healthcare

Website: https://www.utahmed.com

About Utah Medical Products, Inc.

Utah Medical Products, Inc. develops, manufactures, and distributes medical devices for the healthcare industry. The company offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. It also provides GESCO umbilical vessel catheters; DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, the company offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; FINESSE+ generators; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies, and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, it provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS endoscopic irrigation devices; suprapubic catheterization; LIBERTY urinary incontinence treatment and control systems; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN tool to manipulate the uterus in laparoscopic procedures. Additionally, the company offers DELTRAN, a disposable pressure transducer; and pressure monitoring accessories, components, and other molded parts. It serves neonatal intensive care units, labor and delivery departments, women's health centers in hospitals, outpatient clinics, and physician's offices through direct customer service and sales force, independent consultants, and manufacturer representatives. The company was incorporated in 1978 and is headquartered in Midvale, Utah.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996	1995	1994	1993	1992	1991	1990	1989	1988	1987
Revenue	50.22M	52.28M	49.05M	42.18M	46.90M	42.00M	41.41M	39.30M	40.16M	41.28M	40.49M	41.55M	37.86M	25.12M	25.92M	27.78M	28.50M	28.75M	27.69M	26.49M	27.14M	27.36M	26.95M	27.19M	29.44M	27.70M	24.30M	38.70M	42.00M	39.60M	37.00M	36.10M	29.80M	23.90M	17.90M	13.50M	7.60M
Cost of Revenue	20.19M	20.09M	18.14M	16.63M	17.44M	15.69M	15.02M	15.61M	15.97M	16.30M	16.22M	16.25M	15.46M	11.91M	12.13M	12.76M	12.71M	12.61M	11.94M	11.42M	11.25M	11.60M	11.56M	12.07M	11.46M	11.40M	10.20M	18.10M	20.80M	20.70M	19.50M	19.30M	16.90M	14.00M	10.50M	8.40M	4.80M
Gross Profit	30.04M	32.20M	30.92M	25.55M	29.47M	26.31M	26.40M	23.69M	24.19M	24.98M	24.27M	25.31M	22.40M	13.21M	13.79M	15.02M	15.79M	16.15M	15.75M	15.07M	15.89M	15.76M	15.39M	15.13M	17.99M	16.30M	14.10M	20.60M	21.20M	18.90M	17.50M	16.80M	12.90M	9.90M	7.40M	5.10M	2.80M
Gross Profit Ratio	59.81%	61.58%	63.03%	60.57%	62.82%	62.64%	63.73%	60.28%	60.23%	60.52%	59.94%	60.90%	59.17%	52.59%	53.21%	54.06%	55.39%	56.16%	56.89%	56.89%	58.56%	57.61%	57.11%	55.62%	61.09%	58.84%	58.02%	53.23%	50.48%	47.73%	47.30%	46.54%	43.29%	41.42%	41.34%	37.78%	36.84%
Research & Development	560.00K	493.00K	526.00K	486.00K	483.00K	454.00K	447.00K	475.00K	522.00K	460.00K	491.00K	563.00K	518.00K	397.00K	361.00K	359.00K	382.00K	316.00K	320.00K	292.00K	288.00K	285.00K	364.00K	568.00K	719.00K	900.00K	1.00M	1.40M	1.80M	1.50M	0.00	0.00	0.00	0.00	0.00	0.00	0.00
General & Administrative	11.02M	10.41M	10.10M	9.80M	9.61M	5.45M	5.39M	5.36M	5.85M	6.11M	6.16M	6.84M	7.23M	2.35M	2.41M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Selling & Marketing	1.69M	1.51M	1.41M	1.55M	1.74M	1.71M	1.54M	1.67M	2.16M	2.21M	2.79M	2.71M	2.82M	1.54M	1.58M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	12.70M	11.91M	11.51M	11.35M	11.35M	7.16M	6.94M	7.03M	8.01M	8.32M	8.95M	9.55M	10.04M	3.89M	4.00M	4.27M	4.65M	5.00M	6.20M	4.67M	4.88M	4.94M	5.75M	6.19M	6.80M	6.60M	6.10M	5.90M	6.00M	6.10M	7.60M	6.50M	4.30M	3.40M	3.00M	2.50M	1.70M
Other Expenses	0.00	208.00K	15.00K	20.00K	-2.00K	513.00K	54.00K	223.00K	-46.00K	-108.00K	79.00K	-17.00K	0.00	0.00	0.00	0.00	0.00	-1.00K	1.00K	0.00	0.00	0.00	0.00	0.00	2.19M	2.10M	1.50M	1.40M	1.70M	1.30M	1.00M	900.00K	600.00K	500.00K	500.00K	600.00K	400.00K
Operating Expenses	13.26M	12.41M	12.04M	11.84M	11.83M	7.61M	7.38M	7.50M	8.53M	8.78M	9.45M	10.11M	10.56M	4.29M	4.36M	4.63M	5.03M	5.31M	6.52M	4.96M	5.17M	5.22M	6.12M	6.76M	9.71M	9.60M	8.60M	8.70M	9.50M	8.90M	8.60M	7.40M	4.90M	3.90M	3.50M	3.10M	2.10M
Cost & Expenses	33.45M	32.49M	18.14M	28.47M	29.27M	23.30M	22.40M	23.11M	24.51M	25.08M	25.67M	26.36M	26.02M	16.20M	16.48M	17.39M	17.75M	17.92M	18.46M	16.38M	16.42M	16.82M	17.68M	18.83M	21.16M	21.00M	18.80M	26.80M	30.30M	29.60M	28.10M	26.70M	21.80M	17.90M	14.00M	11.50M	6.90M
Interest Income	0.00	0.00	166.00K	112.00K	254.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	16.00K	48.00K	206.00K	543.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	65.00K	289.00K	438.00K	652.00K	859.00K	25.00K	51.00K	198.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	6.37M	7.08M	7.28M	7.21M	6.88M	2.96M	2.77M	2.83M	3.15M	3.36M	3.20M	3.27M	2.77M	607.00K	588.00K	591.00K	597.00K	634.00K	676.00K	809.00K	984.00K	1.17M	1.93M	2.19M	2.19M	2.10M	1.50M	1.40M	1.70M	1.30M	1.00M	900.00K	600.00K	500.00K	500.00K	600.00K	400.00K
EBITDA	24.75M	26.87M	26.16M	20.92M	24.51M	21.65M	21.78M	19.02M	18.84M	19.64M	18.10M	18.46M	14.71M	9.67M	10.22M	11.57M	11.35M	11.47M	9.91M	16.13M	11.71M	11.71M	11.21M	10.56M	10.47M	8.80M	6.97M	13.30M	13.40M	11.30M	9.90M	10.30M	8.60M	6.50M	4.40M	2.60M	1.10M
EBITDA Ratio	49.28%	37.85%	63.03%	32.50%	37.59%	-44.52%	52.73%	60.28%	60.23%	60.52%	36.62%	36.53%	31.28%	100.00%	100.00%	39.37%	37.90%	36.50%	33.67%	39.11%	41.31%	41.04%	39.50%	36.95%	33.79%	27.44%	22.63%	29.72%	29.05%	26.26%	22.16%	25.48%	27.52%	23.85%	22.91%	17.78%	14.47%
Operating Income	16.78M	12.71M	18.88M	6.50M	10.75M	18.70M	19.01M	16.19M	15.65M	16.20M	14.83M	15.20M	11.84M	8.92M	9.43M	10.39M	10.76M	10.84M	9.24M	10.11M	10.72M	10.54M	9.28M	8.37M	8.28M	6.70M	5.50M	11.90M	11.70M	10.00M	8.90M	9.40M	8.00M	6.00M	3.90M	2.00M	700.00K
Operating Income Ratio	33.40%	24.31%	38.49%	15.41%	22.92%	44.52%	45.90%	41.19%	38.97%	39.25%	36.62%	36.57%	31.28%	35.52%	36.39%	37.39%	37.74%	37.68%	33.36%	38.17%	39.51%	38.53%	34.42%	30.77%	28.13%	24.19%	22.63%	30.75%	27.86%	25.25%	24.05%	26.04%	26.85%	25.10%	21.79%	14.81%	9.21%
Total Other Income/Expenses	3.31M	869.00K	181.00K	132.00K	252.00K	762.00K	71.00K	235.00K	-106.00K	-390.00K	-352.00K	-659.00K	-762.00K	118.00K	148.00K	388.00K	1.28M	1.58M	977.00K	-739.00K	454.00K	454.00K	202.00K	53.00K	263.00K	900.00K	1.30M	1.80M	1.20M	900.00K	1.70M	1.20M	300.00K	700.00K	200.00K	0.00	0.00
Income Before Tax	20.09M	20.66M	19.06M	13.84M	17.88M	19.46M	19.08M	16.42M	15.55M	15.81M	14.48M	14.54M	11.08M	9.04M	9.58M	10.78M	12.04M	12.42M	10.21M	10.91M	11.18M	11.00M	9.48M	8.42M	8.55M	7.60M	6.80M	13.70M	12.90M	10.90M	10.60M	10.60M	8.30M	6.70M	4.10M	2.00M	700.00K
Income Before Tax Ratio	40.00%	39.52%	38.86%	32.81%	38.13%	46.33%	46.08%	41.79%	38.71%	38.31%	35.75%	34.99%	29.27%	35.99%	36.97%	38.79%	42.24%	43.19%	36.88%	41.18%	41.18%	40.19%	35.17%	30.96%	29.02%	27.44%	27.98%	35.40%	30.71%	27.53%	28.65%	29.36%	27.85%	28.03%	22.91%	14.81%	9.21%
Income Tax Expense	3.45M	4.19M	4.27M	3.04M	3.16M	904.00K	10.58M	4.29M	3.70M	4.43M	3.07M	4.37M	3.67M	3.03M	3.32M	3.57M	4.13M	4.25M	2.67M	3.74M	3.84M	3.83M	3.55M	3.05M	3.08M	2.70M	2.50M	4.90M	4.50M	3.80M	3.60M	3.70M	2.90M	2.40M	1.50M	600.00K	300.00K
Net Income	16.64M	16.47M	14.79M	10.80M	14.73M	18.55M	8.51M	12.13M	11.84M	11.38M	11.41M	10.17M	7.41M	6.01M	6.26M	7.21M	7.91M	8.17M	7.55M	10.22M	20.76M	7.17M	5.93M	5.37M	5.47M	4.90M	4.30M	8.80M	8.40M	7.10M	7.00M	6.90M	5.40M	4.30M	2.60M	1.40M	400.00K
Net Income Ratio	33.12%	31.51%	30.15%	25.60%	31.40%	44.18%	20.54%	30.86%	29.49%	27.56%	28.17%	24.47%	19.58%	23.94%	24.15%	25.93%	27.73%	28.41%	27.25%	38.59%	76.50%	26.19%	22.02%	19.76%	18.57%	17.69%	17.70%	22.74%	20.00%	17.93%	18.92%	19.11%	18.12%	17.99%	14.53%	10.37%	5.26%
EPS	4.57	4.53	4.05	2.95	3.96	4.97	2.29	3.22	3.14	3.02	3.02	2.74	2.04	1.66	1.73	1.87	2.01	2.07	1.91	2.32	4.59	1.46	1.18	0.90	0.76	0.59	0.51	0.94	0.83	0.68	0.60	0.58	0.46	0.37	0.23	0.13	0.04
EPS Diluted	4.57	4.52	4.04	2.94	3.94	4.95	2.28	3.22	3.14	3.01	3.02	2.74	2.03	1.65	1.72	1.86	1.98	2.02	1.80	2.19	4.25	1.36	1.14	0.90	0.76	0.59	0.51	0.93	0.82	0.68	0.60	0.57	0.46	0.37	0.23	0.13	0.04
Weighted Avg Shares Out	3.64M	3.64M	3.65M	3.66M	3.72M	3.73M	3.72M	3.75M	3.77M	3.77M	3.77M	3.71M	3.63M	3.62M	3.61M	3.84M	3.93M	3.95M	3.95M	4.41M	4.52M	4.91M	5.03M	5.97M	7.19M	8.31M	8.43M	9.36M	10.12M	10.44M	11.67M	11.90M	11.74M	11.62M	11.30M	10.77M	10.00M
Weighted Avg Shares Out (Dil)	3.64M	3.64M	3.66M	3.67M	3.74M	3.75M	3.74M	3.77M	3.77M	3.77M	3.78M	3.71M	3.65M	3.64M	3.63M	3.88M	3.99M	4.04M	4.19M	4.67M	4.88M	5.27M	5.21M	5.97M	7.19M	8.31M	8.43M	9.46M	10.24M	10.44M	11.67M	12.11M	11.74M	11.62M	11.30M	10.77M	10.00M

UTMD Reports Audited Year 2023 and Fourth Quarter Financial Performance

January 30, 2024globenewswire.com

SALT LAKE CITY, UT, Jan. 30, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – With Revenues 4% lower and Net Income and Earnings Per Share 1% higher than in 2022, Utah Medical Products, Inc. (Nasdaq: UTMD) achieved financial results for the...

Utah Medical Products, Inc. Increases Regular Quarterly Dividend

October 31, 2023accesswire.com

SALT LAKE CITY, UT / ACCESSWIRE / October 31, 2023 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty cents ($.30) per share of common stock payable on January 3,...

UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2023

October 26, 2023globenewswire.com

SALT LAKE CITY, UT, Oct. 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Utah Medical Products, Inc. [Nasdaq: UTMD], despite a difficult third calendar quarter (3Q), achieved financial results for nine months (9M) 2023 consistent with those anticipated in its...

Utah Medical Products: Long-Term Positives, But Filshie Clip Overhang Can't Be Ignored

September 26, 2023seekingalpha.com

Utah Medical Products stock has dropped 14% and is at its lowest point this year due to ongoing lawsuits regarding its Filshie clip system. The lawsuits do pose a risk to UTMD's stock price, and a negative outcome could further...

Utah Medical Products, Inc. Announces Quarterly Dividend

August 1, 2023accesswire.com

SALT LAKE CITY, UT / ACCESSWIRE / August 1, 2023 / Utah Medical Products, Inc. (NASDAQ:UTMD) announces that its Board of Directors approved a quarterly cash dividend of twenty-nine and one-half cents ($.295) per share of common stock payable on...

UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2023

July 25, 2023globenewswire.com

SALT LAKE CITY, UT, July 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Utah Medical Products, Inc. [Nasdaq: UTMD] achieved second calendar quarter (2Q) and first half (1H) 2023 financial results consistent with those anticipated in its beginning of year...

1 2 3

Source: https://incomestatements.info
Category: Stock Reports

Utah Medical Products, Inc. (UTMD) Income Statement Analysis – Financial Results

Leave a Reply Cancel reply

Recent Posts

Categories